This morning LCGC North America and LCGC Europe will begin the 2011 Pittcon Theater sessions.
This morning LCGC North America and LCGC Europe will begin the 2011 Pittcon Theater sessions. This dynamic multimedia project will include live interviews with leading luminaries from the world of analytical chemistry and will cover the latest developments, applications and trends in chromatography and spectroscopy.
Today's morning sessions on gas chromatography kick off at 10:00 a.m. with the new editorial director of LCGC North America and Spectroscopy, Laura Bush, interviewing Alyssa Andrews-Ashley from the United States Pharmacopeia on the latest developments in Static headspace GC–MS for the detection of residual solvents.
Jared Anderson, associate professor of analytical chemistry in the Department of Chemistry at the University of Toledo will then offer insights into the evolving role of ionic liquids in the developments of new sorbent coatings for Solid-phase microextraction–gas chromatography (SPME–GC). This is followed by a discussion on Microfabricated gas chromatographs for the sub-ppb determination of complex vapour components by Professor Edward T. Zellers from the Environmental Health Sciences and Environmental Sciences and Chemistry departments at the University of Michigan.
The afternoon sessions on HPLC/UHPLC will begin at 2:00 p.m. with an interview with Michael W. Dong, senior scientist in the Small Molecule Analytical Chemistry and QC division at Genentech who will reveal some of the challenges (and benefits) of using UHPLC in pharmaceutical analysis. Fabrice Gritti, research associate at the University of Tennesee, will then describe the role of Fast analytical chromatography in the design of new stationary phases.
Transferring assays to different laboratories can often be problematic in practice and LCGC EAB member, Mary Ellen McNally, who is a technical fellow in the analytical science department at DuPont Crop Protection will discuss important issues to take into account when comparing UHPLC with HPLC. The final session of the day will describe interesting findings on the physiochemical characteristics of Chromatographic materials in HPLC based on work by Professor Luis A. Colon from the Department of Chemistry at the University of Buffalo.
You are cordially invited to attend these state-of-the-art sessions at Booth #3217.
All attendees will have a chance to win an iPad2 (the winner must be present at the time of the draw).
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.